Listed times are in Central European Time (CET)

WELCOME TO DAY ONE

Marisol Soengas and Karin Dumstrei

SESSION 1 | HAVE AN IDEA AND A PLAN

Chair: Karin Dumstrei

KEYNOTE PRESENTATION

Sadhana Chitale NYU Langone Health, New York, USA

'How to get started'

Q&A 14:40 - 14:55

Ben Travers Knights, UK

'The importance of intellectual property when opening a company'

Q&A 15:25 - 15:40

INDUSTRY SPOTLIGHT - Cancer Research Horizons

Alessia Errico Cancer Research Horizons

'From research to impact: Navigating the Pathways of Research Translation and Commercialisation'

Refreshment break

SESSION 2: FUNDING AND LEGAL ADVICE

Chair: Marisol Soengas

Andy Roberts Bruntwood SciTech, Alderley Park, UK

'Different ways to commercialise your research'

Q&A 16:40 - 16:55

Rudy Dekeyser EQT Life Sciences, Amsterdam, Netherlands

'What do venture groups look for?'

Q&A 17:25 - 17:40

Panel Discussion: 'Get a lawyer!'

Chair: Richard Marais

Thomas Haag, AExeRNA Therapeutics, USA; Barney Leaf, Primas Law, UK; Damià Tormo, Columbus Venture Partners, Madrid, Spain

SUMMARY DAY ONE

WELCOME TO DAY TWO

Daniele Viarisio and Richard Marais

SESSION 3: BUSINESS DEVELOPMENT

Chair: Daniele Viarisio

Birgit Kerber EMBLEM, Heidelberg, Germany

'From bench to product: business development'

Q&A 14:40 - 14:55

Madelon Maurice University of Utrecht, Utrecht, Netherlands

'Where will we work?'

Q&A 15:25 - 15:40

Ian Bell Oncode, Utrecht, Netherlands

'Patent applications, licensing and a timeline for intellectual property considerations when starting up a company'

Q&A 16:10 - 16:25

Refreshment break

SESSION 4: REAL-LIFE EXAMPLES

Chair: Richard Marais

Marisol Soengas CNIO, Madrid, Spain

'Translating research into practise'

Q&A 17:10 - 17:25

KEYNOTE PRESENTATION

Sir Steve Jackson Cambridge University, Cambridge, UK

'It worked for me'

Q&A 17:55 - 18:10

Panel Discussion: 'The challenges of setting up a company - your questions'

Chair: Marisol Soengas

Sir Steve Jackson (Cambridge University, UK), Marisol Soengas (CNIO, Spain), Richard Marais (Oncodrug, UK)

SUMMARY DAY TWO